Diabetes Therapeutics Market Forecast (2024-2031), Size, Share
The Diabetes Therapeutics Market is expected to register a CAGR of 10.3% from 2023 to 2031, with a market size expanding from US$ XX million in 2023 to US$ XX Million by 2031.
The Diabetes Therapeutics Market report covers analysis by Product (Injectables, Oral-Antidiabetic Drugs, and Others). The global analysis is further broken-down at regional level and major countries. The Report Offers the Value in USD for the above analysis and segments.
Purpose of the ReportThe report Diabetes Therapeutics Market by The Insight Partners aims to describe the present landscape and future growth, top driving factors, challenges, and opportunities. This will provide insights to various business stakeholders, such as:
- Technology Providers/Manufacturers: To understand the evolving market dynamics and know the potential growth opportunities, enabling them to make informed strategic decisions.
- Investors: To conduct a comprehensive trend analysis regarding the market growth rate, market financial projections, and opportunities that exist across the value chain.
- Regulatory bodies: To regulate policies and police activities in the market with the aim of minimizing abuse, preserving investor trust and confidence, and upholding the integrity and stability of the market.
Diabetes Therapeutics Market Segmentation
Product- Injectables
- Oral-Antidiabetic Drugs
- Others
Strategic Insights
Diabetes Therapeutics Market Growth Drivers- Epidemiology Analysis: Growing Diabetes Cases Linking Increasing Diabetes Cases with a growing diabetes therapeutics market size, especially in emerging economies.
- Technological Innovation in Insulin Delivery Market Trend: The high adoption rates of smart insulin pens and pumps are making this market grow significantly, and this is the aspect which the competitive analysis suggests.
- Focus on Personalized Medicines: PEST Analysis reflects the trend towards customizing the therapeutic approach with respect to the patient needs, thereby opening up markets in all geographies.
- Rising Prevalence of Diabetes: The increasing prevalence of diabetes, particularly type 2 diabetes, globally is driving the growth of the diabetes therapeutics market. Sedentary lifestyles, poor dietary habits, and increasing obesity rates are significant contributors to this rise.
- Shift Towards Personalized Medicine: The market is seeing a growing trend toward personalized treatment plans for diabetes, where therapies are tailored to an individual’s genetic profile, lifestyle, and disease progression. This approach aims to improve treatment efficacy and minimize side effects.
- Increased Adoption of Insulin Therapy: Insulin remains a mainstay treatment for both type 1 and type 2 diabetes. The introduction of newer, long-acting, and rapid-acting insulin formulations with fewer injections and better glucose control is fueling the market’s growth.
- Opportunity for Innovative Oral Diabetes Medications: There is an emerging opportunity for pharmaceutical companies to create new oral medications that are able to control blood sugar levels efficiently, minimize the occurrence of side effects, and also provide extra benefits, such as weight loss or cardiovascular protection.
- Emerging Markets: As health care access improves in emerging economies, the demand for diabetes therapeutics is expected to rise. Countries in Asia-Pacific, Africa, and Latin America are becoming key growth markets due to the increasing incidence of diabetes and the growing middle-class population with more access to healthcare.
- Combination Therapies: There will be an increased demand for combination therapies, as they provide improved efficacy and patient convenience in managing complex treatment regimens for diabetes. A significant opportunity exists in the development of new combination drug therapies that target multiple pathways in diabetes management.
Market Report Scope
Key Selling Points
- Comprehensive Coverage: The report comprehensively covers the analysis of products, services, types, and end users of the Diabetes Therapeutics Market, providing a holistic landscape.
- Expert Analysis: The report is compiled based on the in-depth understanding of industry experts and analysts.
- Up-to-date Information: The report assures business relevance due to its coverage of recent information and data trends.
- Customization Options: This report can be customized to cater to specific client requirements and suit the business strategies aptly.
The research report on the Diabetes Therapeutics Market can, therefore, help spearhead the trail of decoding and understanding the industry scenario and growth prospects. Although there can be a few valid concerns, the overall benefits of this report tend to outweigh the disadvantages.
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Have a question?
Mrinal
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
Product, and Geography
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
US, UK, Canada, Germany, France, Italy, Australia, Russia, China, Japan, South Korea, Saudi Arabia, Brazil, Argentina
Frequently Asked Questions
The Diabetes Therapeutics Market is estimated to witness a CAGR of 10.3% from 2023 to 2031.
The major factors driving the market are: Growing diabetes patient population, Technological insulin delivery advancements, Shift to personalized medicine.
Key future trends in this market are - Rising Adoption of GLP-1 Receptor Agonists, Innovations in Insulin Delivery Systems, Growing Focus on Digital Health Integration
Key companies of this market are: AstraZeneca, Boehringer Ingelheim International GmbH, Lilly, Glaxosmithkline Plc, Merck Sharp and Dohme Corp, Novartis AG, Novo Nordisk A/S, Sanofi, Takeda Pharmaceutical Company Limited
The report can be delivered in PDF/PPT format; we can also share excel dataset based on the request.
Some of the customization options available based on request are additional 3-5 company profiles and country-specific analysis of 3-5 countries of your choice. Customizations are to be requested/discussed before making final order confirmation, as our team would review the same and check the feasibility.
TABLE OF CONTENTS
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Diabetes Therapeutic Market - By Products
1.3.2 Diabetes Therapeutic Market - By Region
1.3.2.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. DIABETES THERAPEUTIC MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PORTER'S FIVE FORCES ANALYSIS
4.2.1 Bargaining Power of Buyers
4.2.1 Bargaining Power of Suppliers
4.2.1 Threat of Substitute
4.2.1 Threat of New Entrants
4.2.1 Competitive Rivalry
4.3. EXPERT OPINIONS
5. DIABETES THERAPEUTIC MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. DIABETES THERAPEUTIC MARKET - GLOBAL MARKET ANALYSIS
6.1. DIABETES THERAPEUTIC - GLOBAL MARKET OVERVIEW
6.2. DIABETES THERAPEUTIC - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING/MARKET SHARE
7. DIABETES THERAPEUTIC MARKET - REVENUE AND FORECASTS TO 2028 - PRODUCTS
7.1. OVERVIEW
7.2. PRODUCTS MARKET FORECASTS AND ANALYSIS
7.3. INJECTABLES
7.3.1. Overview
7.3.2. Injectables Market Forecast and Analysis
7.3.3. Insulin Market
7.3.3.1. Overview
7.3.3.2. Insulin Market Forecast and Analysis
7.3.4. Glucagon-like Peptide-1 (GLP-1) Receptor Agonists Market
7.3.4.1. Overview
7.3.4.2. Glucagon-like Peptide-1 (GLP-1) Receptor Agonists Market Forecast and Analysis
7.3.5. Amylinomimetic Drugs Market
7.3.5.1. Overview
7.3.5.2. Amylinomimetic Drugs Market Forecast and Analysis
7.4. ORAL-ANTIDIABETIC DRUGS
7.4.1. Overview
7.4.2. Oral-Antidiabetic Drugs Market Forecast and Analysis
7.4.3. Biguanides Market
7.4.3.1. Overview
7.4.3.2. Biguanides Market Forecast and Analysis
7.4.4. Sulfonylureas Market
7.4.4.1. Overview
7.4.4.2. Sulfonylureas Market Forecast and Analysis
7.4.5. Thiazolidinediones Market
7.4.5.1. Overview
7.4.5.2. Thiazolidinediones Market Forecast and Analysis
7.4.6. Alpha-glucosidase Inhibitors Market
7.4.6.1. Overview
7.4.6.2. Alpha-glucosidase Inhibitors Market Forecast and Analysis
7.4.7. Dipeptidyl Peptidase IV (DPP-4) Inhibitors Market
7.4.7.1. Overview
7.4.7.2. Dipeptidyl Peptidase IV (DPP-4) Inhibitors Market Forecast and Analysis
7.4.8. Meglitinides Market
7.4.8.1. Overview
7.4.8.2. Meglitinides Market Forecast and Analysis
7.4.9. Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors Market
7.4.9.1. Overview
7.4.9.2. Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors Market Forecast and Analysis
7.5. OTHERS
7.5.1. Overview
7.5.2. Others Market Forecast and Analysis
8. DIABETES THERAPEUTIC MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
8.1. NORTH AMERICA
8.1.1 North America Diabetes Therapeutic Market Overview
8.1.2 North America Diabetes Therapeutic Market Forecasts and Analysis
8.1.3 North America Diabetes Therapeutic Market Forecasts and Analysis - By Products
8.1.4 North America Diabetes Therapeutic Market Forecasts and Analysis - By Countries
8.1.4.1 United States Diabetes Therapeutic Market
8.1.4.1.1 United States Diabetes Therapeutic Market by Products
8.1.4.2 Canada Diabetes Therapeutic Market
8.1.4.2.1 Canada Diabetes Therapeutic Market by Products
8.1.4.3 Mexico Diabetes Therapeutic Market
8.1.4.3.1 Mexico Diabetes Therapeutic Market by Products
8.2. EUROPE
8.2.1 Europe Diabetes Therapeutic Market Overview
8.2.2 Europe Diabetes Therapeutic Market Forecasts and Analysis
8.2.3 Europe Diabetes Therapeutic Market Forecasts and Analysis - By Products
8.2.4 Europe Diabetes Therapeutic Market Forecasts and Analysis - By Countries
8.2.4.1 Germany Diabetes Therapeutic Market
8.2.4.1.1 Germany Diabetes Therapeutic Market by Products
8.2.4.2 France Diabetes Therapeutic Market
8.2.4.2.1 France Diabetes Therapeutic Market by Products
8.2.4.3 Italy Diabetes Therapeutic Market
8.2.4.3.1 Italy Diabetes Therapeutic Market by Products
8.2.4.4 Spain Diabetes Therapeutic Market
8.2.4.4.1 Spain Diabetes Therapeutic Market by Products
8.2.4.5 United Kingdom Diabetes Therapeutic Market
8.2.4.5.1 United Kingdom Diabetes Therapeutic Market by Products
8.2.4.6 Rest of Europe Diabetes Therapeutic Market
8.2.4.6.1 Rest of Europe Diabetes Therapeutic Market by Products
8.3. ASIA-PACIFIC
8.3.1 Asia-Pacific Diabetes Therapeutic Market Overview
8.3.2 Asia-Pacific Diabetes Therapeutic Market Forecasts and Analysis
8.3.3 Asia-Pacific Diabetes Therapeutic Market Forecasts and Analysis - By Products
8.3.4 Asia-Pacific Diabetes Therapeutic Market Forecasts and Analysis - By Countries
8.3.4.1 Australia Diabetes Therapeutic Market
8.3.4.1.1 Australia Diabetes Therapeutic Market by Products
8.3.4.2 China Diabetes Therapeutic Market
8.3.4.2.1 China Diabetes Therapeutic Market by Products
8.3.4.3 India Diabetes Therapeutic Market
8.3.4.3.1 India Diabetes Therapeutic Market by Products
8.3.4.4 Japan Diabetes Therapeutic Market
8.3.4.4.1 Japan Diabetes Therapeutic Market by Products
8.3.4.5 South Korea Diabetes Therapeutic Market
8.3.4.5.1 South Korea Diabetes Therapeutic Market by Products
8.3.4.6 Rest of Asia-Pacific Diabetes Therapeutic Market
8.3.4.6.1 Rest of Asia-Pacific Diabetes Therapeutic Market by Products
8.4. MIDDLE EAST AND AFRICA
8.4.1 Middle East and Africa Diabetes Therapeutic Market Overview
8.4.2 Middle East and Africa Diabetes Therapeutic Market Forecasts and Analysis
8.4.3 Middle East and Africa Diabetes Therapeutic Market Forecasts and Analysis - By Products
8.4.4 Middle East and Africa Diabetes Therapeutic Market Forecasts and Analysis - By Countries
8.4.4.1 South Africa Diabetes Therapeutic Market
8.4.4.1.1 South Africa Diabetes Therapeutic Market by Products
8.4.4.2 Saudi Arabia Diabetes Therapeutic Market
8.4.4.2.1 Saudi Arabia Diabetes Therapeutic Market by Products
8.4.4.3 U.A.E Diabetes Therapeutic Market
8.4.4.3.1 U.A.E Diabetes Therapeutic Market by Products
8.4.4.4 Rest of Middle East and Africa Diabetes Therapeutic Market
8.4.4.4.1 Rest of Middle East and Africa Diabetes Therapeutic Market by Products
8.5. SOUTH AND CENTRAL AMERICA
8.5.1 South and Central America Diabetes Therapeutic Market Overview
8.5.2 South and Central America Diabetes Therapeutic Market Forecasts and Analysis
8.5.3 South and Central America Diabetes Therapeutic Market Forecasts and Analysis - By Products
8.5.4 South and Central America Diabetes Therapeutic Market Forecasts and Analysis - By Countries
8.5.4.1 Brazil Diabetes Therapeutic Market
8.5.4.1.1 Brazil Diabetes Therapeutic Market by Products
8.5.4.2 Argentina Diabetes Therapeutic Market
8.5.4.2.1 Argentina Diabetes Therapeutic Market by Products
8.5.4.3 Rest of South and Central America Diabetes Therapeutic Market
8.5.4.3.1 Rest of South and Central America Diabetes Therapeutic Market by Products
9. INDUSTRY LANDSCAPE
9.1. MERGERS AND ACQUISITIONS
9.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
9.3. NEW PRODUCT LAUNCHES
9.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
10. DIABETES THERAPEUTIC MARKET, KEY COMPANY PROFILES
10.1. ASTRAZENECA
10.1.1. Key Facts
10.1.2. Business Description
10.1.3. Products and Services
10.1.4. Financial Overview
10.1.5. SWOT Analysis
10.1.6. Key Developments
10.2. BOEHRINGER INGELHEIM INTERNATIONAL GMBH
10.2.1. Key Facts
10.2.2. Business Description
10.2.3. Products and Services
10.2.4. Financial Overview
10.2.5. SWOT Analysis
10.2.6. Key Developments
10.3. LILLY
10.3.1. Key Facts
10.3.2. Business Description
10.3.3. Products and Services
10.3.4. Financial Overview
10.3.5. SWOT Analysis
10.3.6. Key Developments
10.4. GLAXOSMITHKLINE PLC
10.4.1. Key Facts
10.4.2. Business Description
10.4.3. Products and Services
10.4.4. Financial Overview
10.4.5. SWOT Analysis
10.4.6. Key Developments
10.5. MERCK SHARP AND DOHME CORP
10.5.1. Key Facts
10.5.2. Business Description
10.5.3. Products and Services
10.5.4. Financial Overview
10.5.5. SWOT Analysis
10.5.6. Key Developments
10.6. NOVARTIS AG
10.6.1. Key Facts
10.6.2. Business Description
10.6.3. Products and Services
10.6.4. Financial Overview
10.6.5. SWOT Analysis
10.6.6. Key Developments
10.7. NOVO NORDISK A/S
10.7.1. Key Facts
10.7.2. Business Description
10.7.3. Products and Services
10.7.4. Financial Overview
10.7.5. SWOT Analysis
10.7.6. Key Developments
10.8. SANOFI
10.8.1. Key Facts
10.8.2. Business Description
10.8.3. Products and Services
10.8.4. Financial Overview
10.8.5. SWOT Analysis
10.8.6. Key Developments
10.9. TAKEDA PHARMACEUTICAL COMPANY LIMITED
10.9.1. Key Facts
10.9.2. Business Description
10.9.3. Products and Services
10.9.4. Financial Overview
10.9.5. SWOT Analysis
10.9.6. Key Developments
10.10. PFIZER INC
10.10.1. Key Facts
10.10.2. Business Description
10.10.3. Products and Services
10.10.4. Financial Overview
10.10.5. SWOT Analysis
10.10.6. Key Developments
11. APPENDIX
11.1. ABOUT THE INSIGHT PARTNERS
11.2. GLOSSARY OF TERMS
"
The List of Companies
- AstraZeneca
- Boehringer Ingelheim International GmbH
- Lilly
- Glaxosmithkline Plc
- Merck Sharp and Dohme Corp
- Novartis AG
- Novo Nordisk A/S
- Sanofi
- Takeda Pharmaceutical Company Limited
- Pfizer Inc
- Glenmark
- FDC
- Himalaya Wellness Company
- Janssen Global Services, LLC
- Alembic Pharmaceuticals
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For